$KRBP
Kiromic Biopharma, Inc.

2024 Q1 Form 10-K Financial Statement

#000155837024003520 Filed on March 19, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.204M $2.517M $10.71M
YoY Change -21.06% -29.91% -39.39%
% of Gross Profit
Research & Development $3.022M $2.800M $9.625M
YoY Change 45.64% -15.9% -30.86%
% of Gross Profit
Depreciation & Amortization $557.0K $555.6K $2.221M
YoY Change 0.22% 0.13% 32.73%
% of Gross Profit
Operating Expenses $5.113M $5.318M $19.94M
YoY Change 7.02% -23.17% -35.92%
Operating Profit -$5.113M -$19.94M
YoY Change 7.02% -35.92%
Interest Expense -$1.071M -$632.9K -$1.852M
YoY Change 141.22% 296.55% -1212.43%
% of Operating Profit
Other Income/Expense, Net $36.00K $1.260M $2.572M
YoY Change -145.63%
Pretax Income -$6.148M -$4.691M -$20.95M
YoY Change 15.99% -33.63% -39.68%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$6.148M -$5.660M -$20.95M
YoY Change 15.99% -20.89% -39.68%
Net Earnings / Revenue
Basic Earnings Per Share -$1.00 -$12.59
Diluted Earnings Per Share -$1.00 -$4.46 -$12.59
COMMON SHARES
Basic Shares Outstanding 1.288M 1.258M 1.098M
Diluted Shares Outstanding 1.305M 1.098M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.676M $3.204M $3.204M
YoY Change 78.94% 396.59% 396.59%
Cash & Equivalents $3.676M $3.204M $3.204M
Short-Term Investments
Other Short-Term Assets $1.892M $1.226M $1.226M
YoY Change 29.38% 17.47% 17.47%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $5.568M $4.430M $4.430M
YoY Change 58.33% 162.3% 162.3%
LONG-TERM ASSETS
Property, Plant & Equipment $5.650M $6.175M $7.718M
YoY Change -25.47% -24.11% -24.74%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $21.00K $21.40K $21.40K
YoY Change -13.93% -12.3% -12.3%
Total Long-Term Assets $7.060M $7.739M $7.739M
YoY Change -26.39% -24.71% -24.71%
TOTAL ASSETS
Total Short-Term Assets $5.568M $4.430M $4.430M
Total Long-Term Assets $7.060M $7.739M $7.739M
Total Assets $12.63M $12.17M $12.17M
YoY Change -3.66% 1.68% 1.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.000M $2.136M $2.136M
YoY Change -75.47% -70.77% -70.77%
Accrued Expenses $4.901M $4.242M $4.242M
YoY Change 184.12% 163.81% 163.81%
Deferred Revenue
YoY Change
Short-Term Debt $192.0K $14.00M $14.00M
YoY Change -51.28% 2412.56% 220.58%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $19.09M $20.38M $20.38M
YoY Change -3.86% 53.41% 53.41%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $747.0K $911.5K $911.5K
YoY Change -46.2% -41.0% -41.0%
Total Long-Term Liabilities $747.0K $911.5K $911.5K
YoY Change -46.2% -79.56% -79.56%
TOTAL LIABILITIES
Total Short-Term Liabilities $19.09M $20.38M $20.38M
Total Long-Term Liabilities $747.0K $911.5K $911.5K
Total Liabilities $19.84M $21.29M $21.29M
YoY Change -6.63% 20.0% 20.0%
SHAREHOLDERS EQUITY
Retained Earnings -$129.0M -$122.9M
YoY Change 20.28% 20.55%
Common Stock $1.000K $1.258K
YoY Change 2.15% 94.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$7.212M -$9.121M -$9.121M
YoY Change
Total Liabilities & Shareholders Equity $12.63M $12.17M $12.17M
YoY Change -3.66% 1.68% 1.68%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$6.148M -$5.660M -$20.95M
YoY Change 15.99% -20.89% -39.68%
Depreciation, Depletion And Amortization $557.0K $555.6K $2.221M
YoY Change 0.22% 0.13% 32.73%
Cash From Operating Activities -$5.700M -$5.407M -$21.23M
YoY Change 38.09% 31.8% -10.61%
INVESTING ACTIVITIES
Capital Expenditures $21.00K $109.1K $206.6K
YoY Change 90.73% -95.77%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$21.00K -$109.1K -$206.6K
YoY Change 158.53% -95.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $659.1K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.192M 4.341M 23.99M
YoY Change 11.83% -0.37% 514.72%
NET CHANGE
Cash From Operating Activities -5.700M -5.407M -21.23M
Cash From Investing Activities -21.00K -109.1K -206.6K
Cash From Financing Activities 6.192M 4.341M 23.99M
Net Change In Cash 472.0K -1.176M 2.559M
YoY Change -66.5% -653.18% -110.36%
FREE CASH FLOW
Cash From Operating Activities -$5.700M -$5.407M -$21.23M
Capital Expenditures $21.00K $109.1K $206.6K
Free Cash Flow -$5.721M -$5.516M -$21.43M
YoY Change 38.6% 32.62% -25.13%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001792581
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Security Exchange Name
SecurityExchangeName
NONE
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
14000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
648384
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1258460
CY2021Q3 krbp Operating Lease Termination Period After Notice Of Cancellation
OperatingLeaseTerminationPeriodAfterNoticeOfCancellation
P90D
CY2021Q4 krbp Operating Lease Termination Period After Notice Of Cancellation
OperatingLeaseTerminationPeriodAfterNoticeOfCancellation
P90D
CY2022Q2 krbp Operating Lease Termination Period After Notice Of Cancellation
OperatingLeaseTerminationPeriodAfterNoticeOfCancellation
P90D
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-39169
CY2023 dei Entity Registrant Name
EntityRegistrantName
Kiromic BioPharma, Inc.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-4762913
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
7707 Fannin Street
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77054
CY2023 dei City Area Code
CityAreaCode
832
CY2023 dei Local Phone Number
LocalPhoneNumber
968-4888
CY2023 dei Security12b Title
Security12bTitle
Common Shares, par value $0.001 per share
CY2023 dei Trading Symbol
TradingSymbol
KRBP
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
3175902
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1288235
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023 dei Auditor Firm
AuditorFirmId
726
CY2023 dei Auditor Name
AuditorName
Whitley Penn
CY2023 dei Auditor Location
AuditorLocation
Houston, Texas
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3204000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
645200
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1226000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1043700
CY2023Q4 us-gaap Assets Current
AssetsCurrent
4430000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1688900
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6175100
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8136900
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1542500
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2117300
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
21400
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
24400
CY2023Q4 us-gaap Assets
Assets
12169000
CY2022Q4 us-gaap Assets
Assets
11967500
CY2023Q4 us-gaap Secured Debt Current
SecuredDebtCurrent
14000000
CY2022Q4 us-gaap Secured Debt Current
SecuredDebtCurrent
3809900
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2136000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7308100
CY2023Q4 krbp Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
1673400
CY2022Q4 krbp Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
881600
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1937900
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
142100
CY2022Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
557200
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
631000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
584400
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
20378300
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13283300
CY2022Q4 us-gaap Convertible Subordinated Debt Noncurrent
ConvertibleSubordinatedDebtNoncurrent
2914000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
911500
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1544900
CY2023Q4 us-gaap Liabilities
Liabilities
21289800
CY2022Q4 us-gaap Liabilities
Liabilities
17742200
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
60000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
60000000
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
14000
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
16205500
CY2022Q4 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
2
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1258460
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
648384
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1258
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
648
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
113774740
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
96172152
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-122896800
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-101947500
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-9120800
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-5774700
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12169000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11967500
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9624900
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13920400
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10314400
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17193900
CY2023 us-gaap Operating Expenses
OperatingExpenses
19939300
CY2022 us-gaap Operating Expenses
OperatingExpenses
31114300
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-19939300
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-31114300
CY2023 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1852200
CY2022 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
166500
CY2023 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-1730000
CY2022 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-3463000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2572200
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
12800
CY2023 krbp Other Income Expense
OtherIncomeExpense
-1010000
CY2022 krbp Other Income Expense
OtherIncomeExpense
-3616700
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-20949300
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-34731000
CY2023 krbp Earnings Per Preferred Share Basic
EarningsPerPreferredShareBasic
-1103.73
CY2023 krbp Earnings Per Preferred Share Diluted
EarningsPerPreferredShareDiluted
-1103.73
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-12.59
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-12.59
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-64.42
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-64.42
CY2023 krbp Weighted Average Number Of Preferred Shares Outstanding Basic
WeightedAverageNumberOfPreferredSharesOutstandingBasic
8773
CY2023 krbp Weighted Average Number Of Preferred Shares Outstanding Diluted
WeightedAverageNumberOfPreferredSharesOutstandingDiluted
8773
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4865500
CY2023 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
24000000
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1097630
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1097630
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
544475
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
544475
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
27319800
CY2022 krbp Adjustments To Additional Paid In Capital Amortization Of Common Stock Discount
AdjustmentsToAdditionalPaidInCapitalAmortizationOfCommonStockDiscount
344800
CY2022 krbp Adjustments To Additional Paid In Capital Warrant Fair Value
AdjustmentsToAdditionalPaidInCapitalWarrantFairValue
344800
CY2022 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
399400
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1237100
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-34731000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-5774700
CY2023 krbp Adjustments To Additional Paid In Capital Amortization Of Common Stock Discount
AdjustmentsToAdditionalPaidInCapitalAmortizationOfCommonStockDiscount
344700
CY2023 krbp Adjustments To Additional Paid In Capital Warrant Fair Value
AdjustmentsToAdditionalPaidInCapitalWarrantFairValue
344700
CY2023 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
2914000
CY2023 krbp Stock Issued During Period Preferred Stock New Issues Value
StockIssuedDuringPeriodPreferredStockNewIssuesValue
14000000
CY2023 krbp Stock Issued During Period Commitment Value
StockIssuedDuringPeriodCommitmentValue
659100
CY2023 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
111200
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
141300
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-20949300
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-9120800
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-20949300
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-34731000
CY2023 us-gaap Depreciation
Depreciation
2221100
CY2022 us-gaap Depreciation
Depreciation
1673400
CY2023 us-gaap Operating Lease Expense
OperatingLeaseExpense
574800
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
394200
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
141300
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
1237100
CY2022 krbp Gain Loss Related To Litigation Settlement Net Of Cash Payments
GainLossRelatedToLitigationSettlementNetOfCashPayments
-3313400
CY2022 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
12800
CY2022 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
9900
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-16200
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
179300
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-662400
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5034700
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3790800
CY2023 krbp Increase Decrease In Litigation Liability
IncreaseDecreaseInLitigationLiability
447500
CY2023 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
344300
CY2022 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
140600
CY2023 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
1795800
CY2022 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
142100
CY2023 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-586800
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-382200
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21225300
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23745900
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
206600
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4880500
CY2022 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
15000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-206600
CY2022 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
4000000
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
659100
CY2023 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
111200
CY2022 us-gaap Proceeds From Bank Debt
ProceedsFromBankDebt
610700
CY2023 us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
557200
CY2022 us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
508000
CY2022 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
200000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
23990700
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3902700
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2558800
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-24708700
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
645200
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25353900
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3204000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
645200
CY2023 us-gaap Interest Paid Net
InterestPaidNet
56400
CY2022 us-gaap Interest Paid Net
InterestPaidNet
12200
CY2022 krbp Right Of Use Asset Obtained In Exchange For Operating Lease Liability Asc842 Implementation
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityAsc842Implementation
2232700
CY2023 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
14000000
CY2023 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
2914000
CY2022 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
399400
CY2023 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
52700
CY2022 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1303000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
303662
CY2023 krbp Deferred Financing Costs Waived
DeferredFinancingCostsWaived
364700
CY2023Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
30
CY2023 krbp Renegotiated Service Agreement Increase Decrease In Accounts Payable
RenegotiatedServiceAgreementIncreaseDecreaseInAccountsPayable
-1100000
CY2023 krbp Renegotiated Service Agreement Increase Decrease In Accounts Payable
RenegotiatedServiceAgreementIncreaseDecreaseInAccountsPayable
-1100000
CY2023Q4 krbp Renegotiated Service Agreement Increase Decrease In Deferred Finance Costs
RenegotiatedServiceAgreementIncreaseDecreaseInDeferredFinanceCosts
-360000
CY2023 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
740000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21225300
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-122896800
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="-sec-ix-redline:true;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Use of Estimates</b><span style="font-family:'Times New Roman','Times','serif';">—The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include determination of the fair value of common stock and related stock-based compensation, warrants to purchase common stock underlying shares of Series B Preferred Stock and public offering common stock, and estimating services incurred by third-party service providers used to recognize research and development expense.</span></p>
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10837200
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4921400
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2700300
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Concentrations of Credit Risk and Other Uncertainties</b>—Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. Substantially all of the Company’s cash and cash equivalents were deposited in accounts at a small number of national financial institutions. Account balances may at times exceed federally-insured limits. The Company has not incurred losses related to these cash and cash equivalents deposited at financial institutions and management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash is held.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company is subject to certain risks and uncertainties from changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: the ability to obtain regulatory approval and market acceptance of, and reimbursement for, the Company’s product candidates; the performance of third-party clinical research organizations and manufacturers; protection of the intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; the Company’s ability to attract and retain employees necessary to support commercial success; and changes in the industry or customer requirements including the emergence of competitive products with new capabilities.</p>
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6175100
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8136900
CY2022 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2023 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-20949300
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-34731000
CY2023 krbp Adjustments To Additional Paid In Capital Warrant Discount Amortization
AdjustmentsToAdditionalPaidInCapitalWarrantDiscountAmortization
99900
CY2022 krbp Adjustments To Additional Paid In Capital Warrant Discount Amortization
AdjustmentsToAdditionalPaidInCapitalWarrantDiscountAmortization
100000
CY2023 krbp Common Stock Amortization Of Discount
CommonStockAmortizationOfDiscount
244800
CY2022 krbp Common Stock Amortization Of Discount
CommonStockAmortizationOfDiscount
244800
CY2023 krbp Dividends Preferred Stock Undeclared
DividendsPreferredStockUndeclared
2205500
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-23499500
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-35075800
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11096500
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
4000000
CY2022Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
190100
CY2023Q4 us-gaap Secured Debt Current
SecuredDebtCurrent
14000000
CY2022Q4 us-gaap Secured Debt Current
SecuredDebtCurrent
3809900
CY2022 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-3463000
CY2023 us-gaap Depreciation
Depreciation
2221100
CY2022 us-gaap Depreciation
Depreciation
1673400
CY2023Q4 us-gaap Litigation Reserve Current
LitigationReserveCurrent
447500
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
864900
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
668700
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
361000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
212900
CY2023Q4 krbp Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
1673400
CY2022Q4 krbp Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
881600
krbp Number Of Promissory Notes Issued
NumberOfPromissoryNotesIssued
13
krbp Debt Instrument Aggregate Principal Of Notes Issued
DebtInstrumentAggregatePrincipalOfNotesIssued
28000000
CY2023Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
24000000
CY2023 krbp Number Of Promissory Notes Outstanding
NumberOfPromissoryNotesOutstanding
6
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
14000000
CY2022Q4 us-gaap Convertible Subordinated Debt Noncurrent
ConvertibleSubordinatedDebtNoncurrent
2914000
CY2023 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
220500
CY2022 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
291800
CY2022 us-gaap Lease Practical Expedients Package
LeasePracticalExpedientsPackage
true
CY2021Q3 krbp Operating Lease Additional Square Footage
OperatingLeaseAdditionalSquareFootage
15385
CY2021Q4 krbp Number Of Lease Amendments
NumberOfLeaseAmendments
2
CY2021Q4 krbp Operating Lease Additional Square Footage
OperatingLeaseAdditionalSquareFootage
3684
CY2022Q2 krbp Operating Lease Additional Square Footage
OperatingLeaseAdditionalSquareFootage
9352
CY2022Q2 krbp Lessee Operating Lease Payments Per Month Years One And Two
LesseeOperatingLeasePaymentsPerMonthYearsOneAndTwo
4800
CY2022Q2 krbp Lessee Operating Lease Payments Per Month Years Three And Four
LesseeOperatingLeasePaymentsPerMonthYearsThreeAndFour
4896
CY2022Q2 krbp Lessee Operating Lease Payments Per Month Year Five
LesseeOperatingLeasePaymentsPerMonthYearFive
5000
CY2022Q2 krbp Operating Lease Lease Cancellation Termination Payment Number Of Months Rent
OperatingLeaseLeaseCancellationTerminationPaymentNumberOfMonthsRent
3
CY2022Q3 krbp Operating Lease Additional Square Footage
OperatingLeaseAdditionalSquareFootage
1458
CY2022Q3 krbp Lessee Operating Lease Payments Per Month Year One
LesseeOperatingLeasePaymentsPerMonthYearOne
2430
CY2022Q3 krbp Lessee Operating Lease Payments Per Month Years Two And Three
LesseeOperatingLeasePaymentsPerMonthYearsTwoAndThree
2490
CY2022Q3 krbp Lessee Operating Lease Payments Per Month Year Five
LesseeOperatingLeasePaymentsPerMonthYearFive
2552
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1542500
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2117300
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1542500
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2117300
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
631000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
584400
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
911500
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1544900
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1542500
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2129300
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
716100
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
663100
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y4M2D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y4M2D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0712
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0712
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
717600
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
724700
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
242800
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1685100
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
142600
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1542500
CY2022 krbp Short Term Lease Monthly Rental Payments
ShortTermLeaseMonthlyRentalPayments
2500
CY2022 us-gaap Short Term Lease Cost
ShortTermLeaseCost
22500
CY2023Q2 krbp Number Of Suites Subleased
NumberOfSuitesSubleased
3
CY2023Q2 krbp Operating Leases Monthly Rent Sublease Rentals
OperatingLeasesMonthlyRentSubleaseRentals
6444
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
60000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
60000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1258460
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
648384
CY2023Q3 krbp Number Of Exchange Agreements
NumberOfExchangeAgreements
2
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2100
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2100
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
16178000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
12668900
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
470700
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3371900
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2156300
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
874400
CY2023Q4 krbp Deferred Tax Assets Irc Section174 Research And Experimental Expenditures
DeferredTaxAssetsIrcSection174ResearchAndExperimentalExpenditures
3206600
CY2022Q4 krbp Deferred Tax Assets Irc Section174 Research And Experimental Expenditures
DeferredTaxAssetsIrcSection174ResearchAndExperimentalExpenditures
2293000
CY2023Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
260200
CY2022Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
105800
CY2023Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
81600
CY2022Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
88500
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
323900
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
428400
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
139700
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
158500
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
22817000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
19989400
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
22493100
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
19563500
CY2023Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
323900
CY2022Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
425900

Files In Submission

Name View Source Status
0001558370-24-003520-index-headers.html Edgar Link pending
0001558370-24-003520-index.html Edgar Link pending
0001558370-24-003520.txt Edgar Link pending
0001558370-24-003520-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
krbp-20231231.xsd Edgar Link pending
krbp-20231231x10k.htm Edgar Link pending
krbp-20231231x10k001.jpg Edgar Link pending
krbp-20231231x10k002.jpg Edgar Link pending
krbp-20231231x10k003.jpg Edgar Link pending
krbp-20231231x10k004.jpg Edgar Link pending
krbp-20231231x10k005.jpg Edgar Link pending
krbp-20231231x10k006.jpg Edgar Link pending
krbp-20231231x10k007.jpg Edgar Link pending
krbp-20231231x10k008.jpg Edgar Link pending
krbp-20231231x10k009.jpg Edgar Link pending
krbp-20231231x10k010.jpg Edgar Link pending
krbp-20231231x10k011.jpg Edgar Link pending
krbp-20231231x10k012.jpg Edgar Link pending
krbp-20231231x10k013.jpg Edgar Link pending
krbp-20231231x10k014.jpg Edgar Link pending
krbp-20231231x10k015.jpg Edgar Link pending
krbp-20231231xex21d1.htm Edgar Link pending
krbp-20231231xex23d1.htm Edgar Link pending
krbp-20231231xex31d1.htm Edgar Link pending
krbp-20231231xex31d2.htm Edgar Link pending
krbp-20231231xex32d1.htm Edgar Link pending
krbp-20231231xex32d2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
krbp-20231231_def.xml Edgar Link unprocessable
krbp-20231231_lab.xml Edgar Link unprocessable
krbp-20231231_pre.xml Edgar Link unprocessable
krbp-20231231x10k_htm.xml Edgar Link completed
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
krbp-20231231_cal.xml Edgar Link unprocessable